Download File - JOHN J. HADDAD, Ph.D.

Therapeutic and Prophylactic Cancer Vaccines 67
49. Sasagawa T, Pushko P, Steers G, et al. Synthesis and assembly of virus-like particles
of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces
pombe. Virology 1995; 206(1):126–135.
50. Kirnbauer R, Booy F, Cheng N, et al. Papillomavirus L1 major capsid protein selfassembles
into virus-like particles that are highly immunogenic. Proc Natl Acad Sci
USA 1992; 89(24):12180–12184.
51. Zhou J, Sun XY, Davies H, et al. Definition of linear antigenic regions of the HPV16
L1 capsid protein using synthetic virion-like particles. Virology 1992; 189(2):592–599.
52. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus
type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and
L2 capsid proteins. J Virol 1993; 67(1):315–322.
53. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with viruslike particles
from cottontail rabbit papillomavirus (CRPV) can protect against experimental
CRPV infection. J Virol 1995; 69(6):3959–3963.
54. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus
L1 protein completely prevents the development of viral mucosal papillomas. Proc
Natl Acad Sci USA 1995; 92(25):11553–11557.
55. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus
(types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised
double-blind placebo-controlled multicentre phase II efficacy trial. Lancet
Oncol 2005; 6(5):271–278.
56. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration
of a vaccine targeting human papillomavirus types 6, 11, 16, and 18.
Vaccine 2006; 24(27–28):5571–5583.
57. De Bruijn ML, Greenstone HL, Vermeulen H, et al. L1-specific protection from tumor
challenge elicited by HPV16 virus-like particles. Virology 1998; 250(2):371–376.
58. Selvakumar R, Borenstein LA, Lin YL, et al. Immunization with nonstructural
proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virusinduced
papillomas. J Virol 1995; 69(1):602–605.
59. Halpert R, Fruchter RG, Sedlis A, et al. Human papillomavirus and lower genital
neoplasia in renal transplant patients. Obstet Gynecol 1986; 68(2):251–258.
60. Laga M, Icenogle JP, Marsella R, et al. Genital papillomavirus infection and cervical
dysplasia: opportunistic complications of HIV infection. Int J Cancer 1992; 50(1):45–48.
61. Meyer T, Arndt R, Nindl I, et al. Association of human papillomavirus infections with
cutaneous tumors in immunosuppressed patients. Transpl Int 2003; 16(3):146–153.
62. Petry KU, Scheffel D, Bode U, et al. Cellular immunodeficiency enhances the
progression of human papillomavirus-associated cervical lesions. Int J Cancer 1994;
57(6):836–840.
63. Benton C, Shahidullah H, Hunter JAA. Human papillomavirus in the immunosuppressed.
Papillomavirus Report 1992:23–26.
64. Aiba S, Rokugo M, Tagami H. Immunohistologic analysis of the phenomenon of
spontaneous regression of numerous flat warts. Cancer 1986; 58(6):1246–1251.
65. Iwatsuki K, Tagami H, Takigawa M, et al. Plane warts under spontaneous regression.
Immunopathologic study on cellular constituents leading to the inflammatory reaction.
Arch Dermatol 1986; 122(6):655–659.
66. Munger K, Phelps WC, Bubb V, et al. The E6 and E7 genes of the human papillomavirus
type 16 together are necessary and sufficient for transformation of primary
human keratinocytes. J Virol 1989; 63(10):4417–4421.